Research and Clinical Trials
Our research into brain tumors, spinal tumors, and other neurological disorders is bringing new hope to patients affected by these disorders. Our clinical trials enable our researchers to develop new medications and medical therapies. All trials are open for patients who are diagnosed with Glioblastoma (GBM).
Here are some of the research projects currently underway:
A Pivotal Randomized, Open-label Study of Optune® (TTFields, 200kHz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Lead Researcher: Dr. Lyndon Kim
Sponsor: Novocure TRIDENT - Glioblastoma Clinical Trial | Novocure Trials
Summary: To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma
Lead Researcher: Dr. Lyndon Kim
Sponsor: Imvax Inc. Imvax » Turning the complexity of solid tumors against them
Summary: The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.
GCAR AGILE: GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)
Lead Researcher: Dr. Lyndon Kim
Sponsor: GCAR (Global Coalition for Adaptive Research)
GBM AGILE | Overview | Global Coalition for Adaptive Research (gcaresearch.org)
Summary: Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Learn More